We are live on ! Find out more
NVS icon

Novartis

937 hedge funds and large institutions have $22.2B invested in Novartis in 2017 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 348 increasing their positions, 336 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more call options, than puts

Call options by funds: $41.3M | Put options by funds: $22.2M

59% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 44

2% more funds holding

Funds holding: 920937 (+17)

4% more repeat investments, than reductions

Existing positions increased: 348 | Existing positions reduced: 336

2% more capital invested

Capital invested by funds: $21.7B → $22.2B (+$474M)

0.06% less ownership

Funds ownership: 11.09%11.03% (-0.06%)

5% less funds holding in top 10

Funds holding in top 10: 4038 (-2)

Holders
937
Holders Change
+17
Holders Change %
+1.85%
% of All Funds
23.36%
Holding in Top 10
38
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-5%
% of All Funds
0.95%
New
70
Increased
348
Reduced
336
Closed
44
Calls
$41.3M
Puts
$22.2M
Net Calls
+$19.2M
Net Calls Change
-$5M
Name Holding Trade Value Shares
Change
Change in
Stake
CTA
226
Chesley Taft & Associates
Illinois
$5.37M +$154K +2,034 +3%
Geode Capital Management
227
Geode Capital Management
Massachusetts
$5.32M +$3.55M +47,026 +212%
GAM
228
Griffin Asset Management
New York
$5.24M +$62.8K +831 +1%
CIBC Asset Management
229
CIBC Asset Management
Ontario, Canada
$5.11M +$5.01M +66,374 New
Creative Planning
230
Creative Planning
Kansas
$5.06M +$326K +4,322 +7%
ARMC
231
American Research & Management Company
Massachusetts
$5.01M
PL
232
Parkwood LLC
Ohio
$5M +$502K +6,649 +11%
AI
233
Ariel Investments
Illinois
$4.95M +$677K +8,964 +16%
CNB
234
Camden National Bank
Maine
$4.93M +$158K +2,091 +3%
WI
235
Welch Investments
Alabama
$4.87M +$171K +2,266 +4%
LNB
236
Ledyard National Bank
$4.87M +$4.49M +59,455 +1,554%
CS
237
Credit Suisse
Switzerland
$4.81M +$3.36M +44,481 +247%
BCM
238
Brookmont Capital Management
Texas
$4.76M -$4.07M -53,857 -47%
EGA
239
Eagle Global Advisors
Texas
$4.72M -$72.7K -963 -2%
GC
240
Grace Capital
Massachusetts
$4.61M +$615K +8,141 +16%
OWD
241
Osborn Williams & Donohoe
Ohio
$4.61M -$90.2K -1,194 -2%
CAM
242
Carret Asset Management
New York
$4.61M -$75K -993 -2%
NCM
243
Narwhal Capital Management
Georgia
$4.56M +$270K +3,572 +6%
HA
244
Hamel Associates
New Jersey
$4.56M -$33.7K -446 -0.7%
SCM
245
Stonebridge Capital Management
California
$4.53M -$149K -1,979 -3%
GCM
246
Garland Capital Management
Washington
$4.44M +$20.9K +277 +0.5%
HKIM
247
Hayek Kallen Investment Management
Alabama
$4.37M -$29.1K -385 -0.7%
FPTW
248
Franklin, Parlapiano, Turner & Welch
Texas
$4.34M +$263K +3,484 +7%
SBH
249
Segall Bryant & Hamill
Illinois
$4.29M +$74.8K +991 +2%
GC
250
Guggenheim Capital
Illinois
$4.29M +$153K +2,020 +4%

NVS Hedge Fund Activity: Q3 2017 in Review

937 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2017, worth a combined $22.2B — up 2.2% from $21.7B a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new NVS positions and 44 closed out — a net gain of 26 holders — while 348 added to existing stakes and 336 trimmed.

The largest buyer was Bank of America, adding an estimated $158M. The largest seller was Dodge & Cox, cutting an estimated $464M.

  • 937 institutional investors held Novartis (NVS) as of Q3 2017, up from 920 in Q2 2017.
  • Funds reported $22.2B of Novartis stock for Q3 2017, up 2.2% quarter-over-quarter.
  • 70 funds opened new Novartis positions in Q3 2017 and 44 closed out, a net change of +26 holders.
  • The largest Novartis buyer in Q3 2017 was Bank of America, an estimated $158M added.
  • The largest Novartis seller in Q3 2017 was Dodge & Cox, an estimated $464M sold.

Based on aggregated 13F filings for Q3 2017.